AR021663A1 - Clatratos de dehidroepiandrosterona y composiciones farmaceuticas correspondientes - Google Patents

Clatratos de dehidroepiandrosterona y composiciones farmaceuticas correspondientes

Info

Publication number
AR021663A1
AR021663A1 ARP990106362A ARP990106362A AR021663A1 AR 021663 A1 AR021663 A1 AR 021663A1 AR P990106362 A ARP990106362 A AR P990106362A AR P990106362 A ARP990106362 A AR P990106362A AR 021663 A1 AR021663 A1 AR 021663A1
Authority
AR
Argentina
Prior art keywords
dehydroepiandrosterone
clarrates
corresponding pharmaceutical
pharmaceutical compositions
insufficiencies
Prior art date
Application number
ARP990106362A
Other languages
English (en)
Original Assignee
Euphar Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euphar Group Srl filed Critical Euphar Group Srl
Publication of AR021663A1 publication Critical patent/AR021663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a clatratos de dehidroepiandrosterona, posiblemente en la forma de sulfatos, en una matriz que consiste de unaciclodextrina y opcionalmente comprende un agente de co-solubilizacion, y la correspondiente composicion farmacéutica adecuada para terapias de sustitucionpara el tratamiento de insuficiencias adrenocorticales.
ARP990106362A 1998-12-18 1999-12-14 Clatratos de dehidroepiandrosterona y composiciones farmaceuticas correspondientes AR021663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002745A IT1304190B1 (it) 1998-12-18 1998-12-18 Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche

Publications (1)

Publication Number Publication Date
AR021663A1 true AR021663A1 (es) 2002-07-31

Family

ID=11381280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106362A AR021663A1 (es) 1998-12-18 1999-12-14 Clatratos de dehidroepiandrosterona y composiciones farmaceuticas correspondientes

Country Status (24)

Country Link
EP (1) EP1140110B1 (es)
JP (1) JP2002532565A (es)
KR (1) KR100693514B1 (es)
CN (1) CN1198620C (es)
AR (1) AR021663A1 (es)
AT (1) ATE243517T1 (es)
AU (1) AU759979B2 (es)
BR (1) BR9916288A (es)
CA (1) CA2355148A1 (es)
CO (1) CO5231137A1 (es)
DE (1) DE69909128T2 (es)
DK (1) DK1140110T3 (es)
EA (1) EA003304B1 (es)
ES (1) ES2203232T3 (es)
HU (1) HU225414B1 (es)
IL (2) IL143776A0 (es)
IT (1) IT1304190B1 (es)
NZ (1) NZ512795A (es)
PE (1) PE20001379A1 (es)
PT (1) PT1140110E (es)
TR (1) TR200101766T2 (es)
TW (1) TWI225791B (es)
WO (1) WO2000037109A2 (es)
ZA (1) ZA200105223B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815860B1 (fr) * 2000-10-26 2003-12-12 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou precurseur ou derive de celle-ci et au moins un agent myorelaxant
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
ITMI20022549A1 (it) * 2002-12-02 2004-06-03 Actimex S R L Composizione quaternaria comprendente come sostanza attiva la propolis.
US20070191404A1 (en) 2004-04-01 2007-08-16 Pierre Bartsch Pharmaceutical compositions of pyrimidine-2,4,6-triones
WO2006137433A1 (ja) * 2005-06-21 2006-12-28 Wakamoto Pharmaceutical Co., Ltd. レボカバスチンを可溶化させた水性薬剤
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
ES2545337T3 (es) * 2011-07-19 2015-09-10 Pantarhei Bioscience B.V. Comprimido que contiene dehidroepiandrosterona (DHEA)
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
EP2986634B1 (en) * 2013-04-19 2019-11-20 University of Houston System Cocrystalline dhea formulations
EP3505154B1 (en) 2017-12-26 2022-04-06 Industrial Technology Research Institute Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
CN1201397A (zh) * 1995-11-13 1998-12-09 萨珀根公司 甾族化合物给药的改进配方

Also Published As

Publication number Publication date
WO2000037109A3 (en) 2000-09-14
PT1140110E (pt) 2003-11-28
ITMI982745A1 (it) 2000-06-18
AU1981000A (en) 2000-07-12
TWI225791B (en) 2005-01-01
ZA200105223B (en) 2002-09-25
IT1304190B1 (it) 2001-03-08
DE69909128T2 (de) 2004-05-06
DK1140110T3 (da) 2003-10-20
TR200101766T2 (tr) 2001-12-21
ES2203232T3 (es) 2004-04-01
CN1333686A (zh) 2002-01-30
HU225414B1 (en) 2006-11-28
BR9916288A (pt) 2001-10-16
NZ512795A (en) 2003-08-29
IL143776A (en) 2007-03-08
WO2000037109A2 (en) 2000-06-29
HUP0104822A2 (hu) 2002-05-29
KR20010086109A (ko) 2001-09-07
CO5231137A1 (es) 2002-12-27
CA2355148A1 (en) 2000-06-29
EA200100674A1 (ru) 2001-12-24
IL143776A0 (en) 2002-04-21
EP1140110B1 (en) 2003-06-25
AU759979B2 (en) 2003-05-01
CN1198620C (zh) 2005-04-27
PE20001379A1 (es) 2000-11-25
EP1140110A2 (en) 2001-10-10
HUP0104822A3 (en) 2002-08-28
JP2002532565A (ja) 2002-10-02
ATE243517T1 (de) 2003-07-15
DE69909128D1 (de) 2003-07-31
KR100693514B1 (ko) 2007-03-14
EA003304B1 (ru) 2003-04-24

Similar Documents

Publication Publication Date Title
AR021663A1 (es) Clatratos de dehidroepiandrosterona y composiciones farmaceuticas correspondientes
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
GT200200114A (es) Champues con alcohol de behenilo
BRPI0508359A (pt) composições de pelìcula
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR9597A (es) Formulaciones de estrogenos conjugados y bazedoxifeno
ES2172024T3 (es) Composicion para el tratamiento del cabello que contiene un complejo de aminoacido-metal.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
EP1469886B8 (en) Lyophilized pharmaceutical composition of propofol
AR041826A1 (es) Formulaciones de liberacion prolongada en formas de suspension
PA8571901A1 (es) Nueva composicion farmaceutica
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
BRPI0611526A2 (pt) composição tópica contendo gelatina
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ES2188894T3 (es) Lactonas macrociclicas perfumadas.
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
GT200400063A (es) Composiciones solidas blandas con sineresis reducida
PE20050359A1 (es) Composiciones topicas que comprenden terbinafina e hidrocortisona
AR036679A1 (es) Formulaciones y uso de las mismas
BR0210063A (pt) Composição estável e uso da mesma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal